Overview A Study of TAS-205 for Duchenne Muscular Dystrophy Status: Completed Trial end date: 2015-09-01 Target enrollment: Participant gender: Summary The objective of this study is to evaluate the safety and pharmacokinetic of TAS-205 in patients with Duchenne Muscular Dystrophy. Phase: Phase 1 Details Lead Sponsor: Taiho Pharmaceutical Co., Ltd.